
TB-500 is not a full protein — it's a 17-amino-acid synthetic fragment built around the LKKTETQ sequence, the segment of full-length Thymosin β-4 responsible for its actin-binding activity. Thymosin β-4 itself is a small, highly conserved intracellular protein found across most mammalian tissue types, and it's one of the most abundant actin-regulating peptides in the cell. TB-500 was designed to carry forward that specific functional motif in a smaller, more stable synthetic form — which is why the research community treats it as a proxy for probing the same actin-binding pathway the parent molecule engages.
Getting the amino acid count right matters here: TB-500 is the 17-residue fragment, not a 7-residue peptide — that's a distinction worth being precise about, since the two numbers get confused in casual research-forum writing.
Actin is the structural protein that gives cells their shape and lets them move. It exists in two states — free monomers (G-actin) and assembled filaments (F-actin) — and the balance between the two governs everything from cell migration to wound-edge closure at a tissue level. TB-500's defining biochemical property is that it binds G-actin monomers through the LKKTETQ motif, which places it directly inside the machinery that controls how and when cells reorganize their internal scaffolding.
This single mechanism has broad downstream implications, because actin dynamics sit upstream of so many cellular processes:
Allan L. Goldstein and colleagues built the foundational published body of work on Thymosin β-4 — decades of research examining its actin-binding chemistry, its role in angiogenesis-related signalling, and its behaviour across various tissue-repair models. Rather than citing specific figures or page numbers from memory, the useful framing for researchers is simply this: Goldstein's group is the recognized reference point in the Thymosin β-4 literature, and TB-500 research today builds directly on the actin-binding mechanism that lineage of work established.
Dubai's research and aesthetic-medicine sector has scaled fast enough that peptide supply logistics can no longer be an afterthought. A Dubai-based cold-chain dispatch point means TB-500 vials aren't sitting in a customs queue or riding a multi-leg freight chain before reaching a bench — they're moving from local stock to local delivery, same day, for any order confirmed before 4 PM.
| Emirate / Area | Delivery window | Cut-off time | Packaging |
|---|---|---|---|
| Dubai (all zones) | Same-day | 4 PM | Insulated + gel pack |
| Abu Dhabi (all zones) | Same-day | 4 PM | Insulated + double gel pack |
| Sharjah & Ajman | 24 hours | 4 PM | Insulated + gel pack |
| Northern Emirates (RAK, Fujairah, UAQ) | 1–2 business days | 4 PM | Reinforced cold-chain |
| Spec | Detail |
|---|---|
| Strength | 10 mg vial |
| Price | AED 399 |
| Sequence | Thymosin β-4 fragment — 17 amino acids, LKKTETQ actin-binding motif |
| Molecular weight | ≈ 1880 Da |
| Purity (HPLC) | ≥ 98.8% |
| Form | White lyophilized powder |
| Storage (lyophilized) | −20°C, desiccated |
| Reconstitution | 2–3 mL bacteriostatic water |
Reconstitution is lab prep, not administration: add bacteriostatic water slowly down the vial wall, swirl — never shake — and refrigerate the solution immediately. REVIVE does not publish or provide dosing, injection-frequency, or self-administration guidance of any kind; that falls outside the scope of a research-use supplier.